Investment
Features
FeesSafety
Academy
More
Pluang+

Compare GameStop Corp. (GME) vs Recursion Pharmaceuticals Inc (RXRX) Price & Performance

GameStop Corp.Trade
Recursion Pharmaceuticals IncTrade

Price performance (Past 24H)

Key statistics

GameStop Corp. vs Recursion Pharmaceuticals Inc — how do they compare? GameStop Corp. trades at $18.46 (market cap $8.44B), while Recursion Pharmaceuticals Inc trades at $3.31 (market cap $1.81B). The key difference: GameStop Corp. is far larger — about 4.7× Recursion Pharmaceuticals Inc's market cap, and Recursion Pharmaceuticals Inc is trading nearer its 52-week high, GameStop Corp. nearer its low. Which is the better fit depends on your goals.

GMERXRX
Market Cap
$8.44B$1.81B
Sector
Consumer CyclicalHealth
52-Week High
$27.69$6.79
52-Week Low
$18.79$2.84
Enterprise Value
$4.42B$1.33B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

GameStop Corp.

GME trades at $18.79, down 1.93% today, with a bearish technical signal from moving averages but oversold RSI readings. Recent earnings beats and a net income margin of 20.45% highlight improving profitability, though revenue declined to $3.82B in 2025. News indicates potential shifts in the proposed eBay acquisition strategy, moving toward a partnership instead of a full takeover.

The outlook is mixed: strong earnings momentum and low debt-to-asset ratio of 0.28 support upside, but bearish analyst consensus (16.67% buy) and revenue contraction pose risks. Investors face dilution concerns from a $1.4B debt-for-stock swap, while collectibles growth offers opportunity.

Recursion Pharmaceuticals Inc

RXRX trades at $3.33, up 1.22% in the last session, with a bearish technical signal and RSI near overbought levels. The company reported a Q2 2026 earnings miss with revenue of $54M and a net loss of $519M, reflecting a net margin of -961.97%. Recent news highlights participation in investor conferences and a Genentech partnership advancement, but competitive pressures and slow revenue growth remain concerns.

Outlook is cautious due to persistent losses and high cash burn, though partnerships provide some validation. Risks include execution challenges in drug discovery and reliance on milestone payments. Analysts show a mixed stance with 40% buy ratings, but the stock faces headwinds from weak profitability and bearish technical trends.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About GameStop Corp.

Global Market Group Ltd. operates an Internet website that connects Chinese manufacturers with international buyers. The Company's customers can post company profiles and product information in standardized formats; post product listings; and trade leads.

Read more on GME

About Recursion Pharmaceuticals Inc

Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.

Read more on RXRX